BioDigit Speech: Integrated Speech Collection and Biomarker Analysis Technology

BioSensics is pleased to announce the launch of BioDigit Speech, a state-of-the-art solution for speech data collection and analysis in clinical trials and research. BioDigit Speech standardizes collection of speech data and measures over 40 speech outcomes by leveraging information in the audio waveform, spectrum, and cepstrum to capture phonatory, articulatory, prosody, and intelligibility features of speech.

BioDigit Speech is developed in part with the support of the National Institute of Health (NIH) and is currently being used in multiple clinical trials and studies in Parkinson's disease, Huntington's disease, progressive supranuclear palsy, ALS, dementia, and Alzheimer's.

BioDigit Speech is integrated into BioDigit Home, a multi-modal platform for remote measurement of motor, speech, and cognitive functions at patients' homes. BioDigit Home includes over 100 digital assessments and complete ePRO capabilities, and is often used in conjunction with the PAMSys sensor for continuous monitoring of physical activity, posture, and falls.

Dr. Vaziri will be discussing our speech studies at the NIH Bridge2AI Voice Symposium on April 19 in Washington D.C., and the Digital Health Innovation Summit on June 6-7 in San Francisco. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.